| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 15, 2012Another Medtronic First in Neuromodulation in Canada
BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
-
Mar 14, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...